Blood-Based Biomarker Analysis for Th2 Airway Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating Th2-high asthma are limited by the need for airway tissue and the lack of specific biomarkers for Th2 inflammation, as existing markers like periostin are not specific due to their production in other tissues and difficulty in measuring IL-13 in serum.
Innovation Solution
A method involving the analysis of IL-13 induced proteins in blood samples using mass spectrometry and other techniques to identify and treat Th2 airway inflammatory diseases, including Th2-high asthma, by administering inhaled corticosteroids or Th2 pathway inhibitors based on the presence and level of specific proteins such as FCGBP, ALOX15, and PAI2.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If airway tissue is used for endotyping, then diagnostic accuracy for Th2 inflammation is improved, but invasiveness and complexity of the procedure increases
Solution Approach 1:
The patent uses blood-based IL-13 and periostin levels as intermediary markers to indirectly assess airway Th2 inflammation without requiring direct airway tissue sampling. This mediator approach maintains diagnostic accuracy while eliminating the invasiveness of bronchoscopy.
Solution Approach 2:
The patent creates a blood-based copy or surrogate of the airway tissue inflammatory signature by measuring IL-13 and periostin levels in peripheral blood, which reflect the Th2 inflammatory state in the airways without requiring actual tissue samples.
2Ease of operation
If periostin is used as a biomarker, then ease of measurement is improved, but specificity for airway inflammation deteriorates due to production in other tissues
Solution Approach 1:
The patent combines measurement of both IL-13 and periostin levels in blood samples. The synergistic use of these two markers maintains the ease of measurement advantage while achieving high specificity for airway Th2 inflammation, as the combination pattern is distinct from other conditions.
Solution Approach 2:
The patent creates a composite biomarker profile using the combination of IL-13 and periostin levels, where the integrated interpretation of both markers provides superior specificity compared to either marker alone, while maintaining practical ease of measurement through standard blood tests.
3Measurement precision
If IL-13 measurement is attempted in serum, then direct measurement of the cytokine is achieved, but measurement feasibility deteriorates due to technical difficulties
Solution Approach 1:
Instead of directly measuring IL-13 cytokine activity in serum (which is technically difficult), the patent measures periostin protein levels as an intermediary downstream effector of IL-13. This mediator approach provides accurate reflection of IL-13 activity while being technically feasible with standard immunoassays.
Solution Approach 2:
The patent replaces the complex mechanical/technical challenge of directly measuring low-concentration IL-13 cytokine in serum with a simpler biochemical measurement of periostin protein, which is more abundant and easier to detect using standard clinical laboratory techniques.
4Ease of operation
If blood-based biomarkers are developed, then ease of sampling is improved, but availability of specific Th2 markers deteriorates
Solution Approach 1:
The patent leverages the natural physiological property that IL-13 stimulation causes airway epithelial cells to secrete periostin into the bloodstream. This self-service mechanism provides a spontaneous, naturally occurring blood-based marker that requires no additional intervention or complex sample collection procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the identification and treatment of Th2 airway inflammatory diseases through a simple blood-based test, improving diagnostic specificity and treatment response prediction by utilizing IL-13 induced proteins as biomarkers.
Implementation Method 1
determining the level of one or more interleukin-13 (IL-13) induced proteins in the sample
Data Source
AI summary
The present invention is related to novel methods for identifying and/or diagnosing and/or treating a population of subjects that are at risk for developing and/or have an inflammatory disease of the airways, including type 2 cytokine-driven airway inflammation.